Immuneering Corporation (NASDAQ:IMRX) Receives $13.25 Consensus Target Price from Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $13.25.

Several research firms have commented on IMRX. Oppenheimer reduced their price objective on Immuneering from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Chardan Capital reaffirmed a “buy” rating and set a $13.00 target price on shares of Immuneering in a research report on Thursday. Mizuho increased their target price on Immuneering from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Wednesday, June 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Immuneering in a research report on Wednesday, June 18th.

Immuneering Stock Down 5.6%

IMRX opened at $3.04 on Friday. The stock’s fifty day moving average is $3.35 and its two-hundred day moving average is $2.18. The company has a market capitalization of $109.41 million, a P/E ratio of -1.61 and a beta of 0.37. Immuneering has a 52 week low of $1.00 and a 52 week high of $4.69.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). Equities analysts anticipate that Immuneering will post -1.86 earnings per share for the current year.

Insider Buying and Selling at Immuneering

In related news, Director Peter Feinberg bought 25,000 shares of the company’s stock in a transaction on Wednesday, June 18th. The shares were acquired at an average price of $2.53 per share, with a total value of $63,250.00. Following the transaction, the director owned 136,766 shares of the company’s stock, valued at $346,017.98. The trade was a 22.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Benjamin J. Zeskind bought 21,000 shares of the company’s stock in a transaction on Wednesday, June 18th. The shares were bought at an average cost of $2.39 per share, for a total transaction of $50,190.00. Following the transaction, the chief executive officer directly owned 2,302,852 shares in the company, valued at approximately $5,503,816.28. This represents a 0.92% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 127,507 shares of company stock valued at $334,318. 22.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Immuneering

A number of institutional investors have recently made changes to their positions in IMRX. Rockefeller Capital Management L.P. acquired a new stake in shares of Immuneering in the 4th quarter worth $390,000. XTX Topco Ltd boosted its position in shares of Immuneering by 177.2% in the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after purchasing an additional 20,871 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Immuneering in the 4th quarter worth $47,000. Bridgeway Capital Management LLC boosted its position in shares of Immuneering by 77.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock worth $113,000 after purchasing an additional 22,400 shares in the last quarter. Finally, First Manhattan CO. LLC. acquired a new stake in shares of Immuneering in the 4th quarter worth $71,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.